{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T13:35:08Z","timestamp":1794922508526,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA142543"],"award-info":[{"award-number":["P30CA142543"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["R01 EB025192-01A1"],"award-info":[{"award-number":["R01 EB025192-01A1"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["SIEGWA18XX0"],"award-info":[{"award-number":["SIEGWA18XX0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["HODGES19R1"],"award-info":[{"award-number":["HODGES19R1"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP160157"],"award-info":[{"award-number":["RP160157"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Approximately 10% of Cystic Fibrosis (CF) patients, particularly those with CF transmembrane conductance regulator (\n                    <jats:italic>CFTR<\/jats:italic>\n                    ) gene nonsense mutations, lack effective treatments. The potential of gene correction therapy through delivery of the CRISPR\/Cas system to CF-relevant organs\/cells is hindered by the lack of efficient genome editor delivery carriers. Herein, we report improved Lung Selective Organ Targeting Lipid Nanoparticles (SORT LNPs) for efficient delivery of Cas9 mRNA, sgRNA, and donor ssDNA templates, enabling precise homology-directed repair-mediated gene correction in CF models. Optimized Lung SORT LNPs deliver mRNA to lung basal cells in Ai9 reporter mice. SORT LNP treatment successfully corrected the\n                    <jats:italic>CFTR<\/jats:italic>\n                    mutations in homozygous G542X mice and in patient-derived human bronchial epithelial cells with homozygous F508del mutations, leading to the restoration of CFTR protein expression and chloride transport function. This proof-of-concept study will contribute to accelerating the clinical development of mRNA LNPs for CF treatment through CRISPR\/Cas gene correction.\n                  <\/jats:p>","DOI":"10.1038\/s41467-023-42948-2","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T12:01:47Z","timestamp":1699704107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":195,"title":["Lung SORT LNPs enable precise homology-directed repair mediated CRISPR\/Cas genome correction in cystic fibrosis models"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2823-9721","authenticated-orcid":false,"given":"Tuo","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0215-6095","authenticated-orcid":false,"given":"Yehui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5213-5084","authenticated-orcid":false,"given":"Qiang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Traylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4563-5486","authenticated-orcid":false,"given":"Lindsay T.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Coquelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xizhen","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8925-5645","authenticated-orcid":false,"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5604-7479","authenticated-orcid":false,"given":"Yufen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Hodges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3823-1931","authenticated-orcid":false,"given":"Daniel J.","family":"Siegwart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,11]]},"reference":[{"key":"42948_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.gendis.2018.11.005","volume":"6","author":"CA Hodges","year":"2019","unstructured":"Hodges, C. A. & Conlon, R. A. Delivering on the promise of gene editing for cystic fibrosis. Genes Dis. 6, 97\u2013108 (2019).","journal-title":"Genes Dis."},{"key":"42948_CR2","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.3390\/cells10102793","volume":"10","author":"I Fajac","year":"2021","unstructured":"Fajac, I. & Sermet, I. Therapeutic approaches for patients with cystic fibrosis not eligible for current CFTR modulators. Cells 10, 2793 (2021).","journal-title":"Cells"},{"key":"42948_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","volume":"8","author":"SC Bell","year":"2020","unstructured":"Bell, S. C. et al. The future of cystic fibrosis care: a global perspective. Lancet Respir. Med. 8, 65\u2013124 (2020).","journal-title":"Lancet Respir. Med."},{"key":"42948_CR4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1080\/17476348.2019.1634547","volume":"13","author":"KM Miah","year":"2019","unstructured":"Miah, K. M., Hyde, S. C. & Gill, D. R. Emerging gene therapies for cystic fibrosis. Expert Rev. Respir. Med. 13, 709\u2013725 (2019).","journal-title":"Expert Rev. Respir. Med."},{"key":"42948_CR5","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.3390\/ijms21113903","volume":"21","author":"G Maule","year":"2020","unstructured":"Maule, G., Arosio, D. & Cereseto, A. Gene therapy for cystic fibrosis: Progress and challenges of genome editing. Int. J. Mol. Sci. 21, 3903 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"42948_CR6","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1016\/j.jcf.2019.12.012","volume":"19","author":"A Christopher Boyd","year":"2020","unstructured":"Christopher Boyd, A. et al. New approaches to genetic therapies for cystic fibrosis. J. Cyst. Fibros. 19, S54\u2013S59 (2020).","journal-title":"J. Cyst. Fibros."},{"key":"42948_CR7","doi-asserted-by":"publisher","first-page":"9243","DOI":"10.1021\/acsnano.0c04707","volume":"14","author":"T Wei","year":"2020","unstructured":"Wei, T. et al. Delivery of tissue-targeted scalpels: opportunities and challenges for in vivo CRISPR\/Cas-based genome editing. ACS Nano 14, 9243\u20139262 (2020).","journal-title":"ACS Nano"},{"key":"42948_CR8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong, L. et al. Multiplex genome engineering using CRISPR\/Cas systems. Science 339, 819\u2013823 (2013).","journal-title":"Science"},{"key":"42948_CR9","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816\u2013821 (2012).","journal-title":"Science"},{"key":"42948_CR10","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.1232033","volume":"339","author":"P Mali","year":"2013","unstructured":"Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823\u2013826 (2013).","journal-title":"Science"},{"key":"42948_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nbt.2842","volume":"32","author":"JD Sander","year":"2014","unstructured":"Sander, J. D. & Joung, J. K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat. Biotechnol. 32, 347\u2013355 (2014).","journal-title":"Nat. Biotechnol."},{"key":"42948_CR12","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1021\/acs.accounts.9b00106","volume":"52","author":"D Wilbie","year":"2019","unstructured":"Wilbie, D., Walther, J. & Mastrobattista, E. Delivery aspects of CRISPR\/Cas for in vivo genome editing. Acc. Chem. Res. 52, 1555\u20131564 (2019).","journal-title":"Acc. Chem. Res."},{"key":"42948_CR13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrd.2016.280","volume":"16","author":"H Yin","year":"2017","unstructured":"Yin, H., Kauffman, K. J. & Anderson, D. G. Delivery technologies for genome editing. Nat. Rev. Drug Discov. 16, 387\u2013399 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"42948_CR14","doi-asserted-by":"publisher","first-page":"9874","DOI":"10.1021\/acs.chemrev.6b00799","volume":"117","author":"HX Wang","year":"2017","unstructured":"Wang, H. X. et al. CRISPR\/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery. Chem. Rev. 117, 9874\u20139906 (2017).","journal-title":"Chem. Rev."},{"key":"42948_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.biomaterials.2018.04.031","volume":"171","author":"L Li","year":"2018","unstructured":"Li, L., Hu, S. & Chen, X. Non-viral delivery systems for CRISPR\/Cas9-based genome editing: challenges and opportunities. Biomaterials 171, 207\u2013218 (2018).","journal-title":"Biomaterials"},{"key":"42948_CR16","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1080\/17425247.2018.1517746","volume":"15","author":"DC Luther","year":"2018","unstructured":"Luther, D. C., Lee, Y. W., Nagaraj, H., Scaletti, F. & Rotello, V. M. Delivery approaches for CRISPR\/Cas9 therapeutics in vivo: Advances and challenges. Expert Opin. Drug Deliv. 15, 905\u2013913 (2018).","journal-title":"Expert Opin. Drug Deliv."},{"key":"42948_CR17","doi-asserted-by":"publisher","first-page":"673286","DOI":"10.3389\/fgene.2021.673286","volume":"12","author":"L Duan","year":"2021","unstructured":"Duan, L. et al. Nanoparticle delivery of CRISPR\/Cas9 for genome editing. Front. Genet. 12, 673286 (2021).","journal-title":"Front. Genet."},{"key":"42948_CR18","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1073\/pnas.1520756113","volume":"113","author":"K Zhou","year":"2016","unstructured":"Zhou, K. et al. Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model. Proc. Natl Acad. Sci. USA 113, 520\u2013525 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"42948_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotechnol. 15, 313\u2013320 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"42948_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17029-3","volume":"11","author":"T Wei","year":"2020","unstructured":"Wei, T., Cheng, Q., Min, Y. L., Olson, E. N. & Siegwart, D. J. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat. Commun. 11, 3232 (2020).","journal-title":"Nat. Commun."},{"key":"42948_CR21","doi-asserted-by":"publisher","first-page":"e2109256118","DOI":"10.1073\/pnas.2109256118","volume":"118","author":"SA Dilliard","year":"2021","unstructured":"Dilliard, S. A., Cheng, Q. & Siegwart, D. J. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc. Natl Acad. Sci. USA 118, e2109256118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"42948_CR22","doi-asserted-by":"publisher","first-page":"e2006619","DOI":"10.1002\/adma.202006619","volume":"33","author":"L Farbiak","year":"2021","unstructured":"Farbiak, L. et al. All-in-one dendrimer-based lipid nanoparticles enable precise HDR-mediated gene editing in vivo. Adv. Mater. 33, e2006619 (2021).","journal-title":"Adv. Mater."},{"key":"42948_CR23","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41565-022-01122-3","volume":"17","author":"D Zhang","year":"2022","unstructured":"Zhang, D. et al. Enhancing CRISPR\/Cas gene editing through modulating cellular mechanical properties for cancer therapy. Nat. Nanotechnol. 17, 777\u2013787 (2022).","journal-title":"Nat. Nanotechnol."},{"key":"42948_CR24","doi-asserted-by":"publisher","first-page":"e1805308","DOI":"10.1002\/adma.201805308","volume":"30","author":"Q Cheng","year":"2018","unstructured":"Cheng, Q. et al. Dendrimer-based lipid nanoparticles deliver therapeutic FAH mRNA to normalize liver function and extend survival in a mouse model of hepatorenal tyrosinemia type I. Adv. Mater. 30, e1805308 (2018).","journal-title":"Adv. Mater."},{"key":"42948_CR25","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/anie.201610209","volume":"56","author":"JB Miller","year":"2017","unstructured":"Miller, J. B. et al. Non-viral CRISPR\/Cas gene editing in vitro and in vivo enabled by synthetic nanoparticle co-delivery of Cas9 mRNA and sgRNA. Angew. Chem. Int. Ed. 56, 1059\u20131063 (2017).","journal-title":"Angew. Chem. Int. Ed."},{"key":"42948_CR26","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41563-020-00886-0","volume":"20","author":"S Liu","year":"2021","unstructured":"Liu, S. et al. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR-Cas gene editing. Nat. Mater. 20, 701\u2013710 (2021).","journal-title":"Nat. Mater."},{"key":"42948_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/nbt.3481","volume":"34","author":"CD Richardson","year":"2016","unstructured":"Richardson, C. D., Ray, G. J., DeWitt, M. A., Curie, G. L. & Corn, J. E. Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat. Biotechnol. 34, 339\u2013344 (2016).","journal-title":"Nat. Biotechnol."},{"key":"42948_CR28","doi-asserted-by":"publisher","first-page":"e0199573","DOI":"10.1371\/journal.pone.0199573","volume":"13","author":"DR McHugh","year":"2018","unstructured":"McHugh, D. R. et al. A G542X cystic fibrosis mouse model for examining nonsense mutation directed therapies. PLoS One 13, e0199573 (2018).","journal-title":"PLoS One"},{"key":"42948_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.stem.2019.11.002","volume":"26","author":"S Vaidyanathan","year":"2020","unstructured":"Vaidyanathan, S. et al. High-efficiency, selection-free gene repair in airway stem cells from cystic fibrosis patients rescues CFTR function in differentiated epithelia. Cell Stem Cell 26, 161\u2013171.e164 (2020).","journal-title":"Cell Stem Cell"},{"key":"42948_CR30","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1089\/hum.2020.160","volume":"31","author":"NE King","year":"2020","unstructured":"King, N. E. et al. Correction of airway stem cells: genome editing approaches for the treatment of cystic fibrosis. Hum. Gene Ther. 31, 956\u2013972 (2020).","journal-title":"Hum. Gene Ther."},{"key":"42948_CR31","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1016\/j.ymthe.2020.04.021","volume":"28","author":"S Suzuki","year":"2020","unstructured":"Suzuki, S. et al. Highly efficient gene editing of cystic fibrosis patient-derived airway basal cells results in functional CFTR correction. Mol. Ther. 28, 1684\u20131695 (2020).","journal-title":"Mol. Ther."},{"key":"42948_CR32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41587-019-0032-3","volume":"37","author":"K Clement","year":"2019","unstructured":"Clement, K. et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat. Biotechnol. 37, 224\u2013226 (2019).","journal-title":"Nat. Biotechnol."},{"key":"42948_CR33","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jcf.2021.01.009","volume":"20","author":"DK Crawford","year":"2021","unstructured":"Crawford, D. K. et al. Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids. J. Cyst. Fibros. 20, 436\u2013442 (2021).","journal-title":"J. Cyst. Fibros."},{"key":"42948_CR34","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/nm.3201","volume":"19","author":"JF Dekkers","year":"2013","unstructured":"Dekkers, J. F. et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat. Med 19, 939\u2013945 (2013).","journal-title":"Nat. Med"},{"key":"42948_CR35","first-page":"55159","volume":"120","author":"SF Boj","year":"2017","unstructured":"Boj, S. F. et al. Forskolin-induced swelling in intestinal organoids: an In Vitro assay for assessing drug response in cystic fibrosis patients. J. Vis. Exp. 120, 55159 (2017).","journal-title":"J. Vis. Exp."},{"key":"42948_CR36","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.stem.2020.01.019","volume":"26","author":"MH Geurts","year":"2020","unstructured":"Geurts, M. H. et al. CRISPR-based adenine editors correct nonsense mutations in a cystic fibrosis organoid biobank. Cell Stem Cell 26, 503\u2013510.e507 (2020).","journal-title":"Cell Stem Cell"},{"key":"42948_CR37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","volume":"18","author":"JP Clancy","year":"2019","unstructured":"Clancy, J. P. et al. CFTR modulator theratyping: current status, gaps and future directions. J. Cyst. Fibros. 18, 22\u201334 (2019).","journal-title":"J. Cyst. Fibros."},{"key":"42948_CR38","doi-asserted-by":"publisher","first-page":"246ra297","DOI":"10.1126\/scitranslmed.3008889","volume":"6","author":"G Veit","year":"2014","unstructured":"Veit, G. et al. Some gating potentiators, including VX-770, diminish DeltaF508-CFTR functional expression. Sci. Transl. Med. 6, 246ra297 (2014).","journal-title":"Sci. Transl. Med."},{"key":"42948_CR39","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41587-023-01679-x","volume":"41","author":"B Li","year":"2023","unstructured":"Li, B. et al. Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing. Nat. Biotechnol. 41, 1410\u20131415 (2023).","journal-title":"Nat. Biotechnol."},{"key":"42948_CR40","doi-asserted-by":"publisher","first-page":"1805116","DOI":"10.1002\/adma.201805116","volume":"31","author":"AK Patel","year":"2019","unstructured":"Patel, A. K. et al. Inhaled nanoformulated mRNA polyplexes for protein production in lung epithelium. Adv. Mater. 31, 1805116 (2019).","journal-title":"Adv. Mater."},{"key":"42948_CR41","doi-asserted-by":"publisher","first-page":"eabo0522","DOI":"10.1126\/sciadv.abo0522","volume":"8","author":"AS Piotrowski-Daspit","year":"2022","unstructured":"Piotrowski-Daspit, A. S. et al. In vivo correction of cystic fibrosis mediated by PNA nanoparticles. Sci. Adv. 8, eabo0522 (2022).","journal-title":"Sci. Adv."},{"key":"42948_CR42","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.omtn.2023.06.020","volume":"33","author":"AT Joynt","year":"2023","unstructured":"Joynt, A. T. et al. Protospacer modification improves base editing of a canonical splice site variant and recovery of CFTR function in human airway epithelial cells. Mol. Ther. Nucleic Acids 33, 335\u2013350 (2023).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"42948_CR43","doi-asserted-by":"publisher","first-page":"10558","DOI":"10.1093\/nar\/gkab788","volume":"49","author":"S Krishnamurthy","year":"2021","unstructured":"Krishnamurthy, S. et al. Functional correction of CFTR mutations in human airway epithelial cells using adenine base editors. Nucleic Acids Res. 49, 10558\u201310572 (2021).","journal-title":"Nucleic Acids Res."},{"key":"42948_CR44","first-page":"e16144","volume":"13","author":"A Zaher","year":"2021","unstructured":"Zaher, A., ElSaygh, J., Elsori, D., ElSaygh, H. & Sanni, A. A review of Trikafta: triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy. Cureus 13, e16144 (2021).","journal-title":"Cureus"},{"key":"42948_CR45","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41551-023-01032-2","volume":"7","author":"DV Foss","year":"2023","unstructured":"Foss, D. V. et al. Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes. Nat. Biomed. Eng. 7, 647\u2013660 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"42948_CR46","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1126\/science.abg6155","volume":"373","author":"M Segel","year":"2021","unstructured":"Segel, M. et al. Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudotyped for mRNA delivery. Science 373, 882\u2013889 (2021).","journal-title":"Science"},{"key":"42948_CR47","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","volume":"38","author":"AV Anzalone","year":"2020","unstructured":"Anzalone, A. V., Koblan, L. W. & Liu, D. R. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat. Biotechnol. 38, 824\u2013844 (2020).","journal-title":"Nat. Biotechnol."},{"key":"42948_CR48","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41587-022-01527-4","volume":"41","author":"MTN Yarnall","year":"2022","unstructured":"Yarnall, M. T. N. et al. Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases. Nat. Biotechnol. 41, 500\u2013512 (2022).","journal-title":"Nat. Biotechnol."},{"key":"42948_CR49","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","volume":"18","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat. Protoc. 18, 265\u2013291 (2023).","journal-title":"Nat. Protoc."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-42948-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-42948-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-42948-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T13:02:23Z","timestamp":1699707743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-42948-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,11]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["42948"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-42948-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,11]]},"assertion":[{"value":"25 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A provisional patent application covering compositions, methods, and uses for targeting cystic fibrosis and related disorders has been filed by UT Southwestern naming T.W., Y.S., Q.C. and D.J.S as inventors. D.J.S. discloses financial interests in Signify Bio, ReCode Therapeutics, and Tome Biosciences. D.J.S. is a co-founder and member of the scientific advisory board of ReCode Therapeutics, which has licensed intellectual property from UT Southwestern. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7322"}}